Pharmacovigilance – COVID-19 vaccines – Norway:

Svein R. Andersen, Scientific Director for Vaccines, NOMA

- NOMA member of European regulatory network ➔ Benefit Risk assessment = EU (CHMP) decision.
- National level: Norwegian Institute of Public Health - mandated to decide on how to use COVID-19 vaccines
  - option to undertake benefit-risk assessment at group level
- **Lesson Learned:** With a few exceptions our pharmacovigilance verifies the safety profile seen in clinical trials.
  - Thrombosis with Thrombocytopenia Syndrome (TTS) and myocarditis/pericarditis
- **Pharmacovigilance tools:**
  - **Active spontaneous ADR reporting - HCP and consumers** (electronically submitted).
    ➔ near real-time monitoring of COVID-19 vaccine safety ➔ signals picked up early – e.g., TTS
  - **National population-based health registries incl. the vaccination registry**
    - e.g., risk of myocarditis after vaccination.
  - **Large health survey cohorts (NIPH)**
    - Enrolled on a voluntary basis (vaccinated and unvaccinated): respond to health questionnaires
    - e.g. useful when data on background incidence is limited
  - **Communication:** Summary reports on incoming ADR reports - published weekly
    - The general public expects transparency
- **Vaccine uptake – not negatively affected:** 79-96% depending on the age group (adult population, 2 doses)